Trial Profile
Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2017
Price :
$35
*
At a glance
- Drugs Monalizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Innate Pharma
- 03 Jan 2017 Status changed from recruiting to discontinued.
- 29 Dec 2014 New trial record